Evidence map›Paper›PMID 30323698›Full record

ReviewLung Cancer (Auckland, N.Z.)2018

Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes.

Farkhad Manapov, Lukas Käsmann, Olarn Roengvoraphoj, Maurice Dantes, Nina-Sophie Schmidt-Hegemann, Claus Belka, Chukwuka Eze

Abstract readReview
In one paragraph

Review in Lung Cancer (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Prospective study assessing the feasibility of hippocampal-sparing radiotherapy in lung cancer patients requiring cranial irradiation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Prophylactic cranial irradiation in SCLC.Translational lung cancer research · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Current approaches to the management of brain metastases.Nature reviews. Clinical oncology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Farkhad ManapovDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Lukas KäsmannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Olarn RoengvoraphojDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Maurice DantesDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Nina-Sophie Schmidt-HegemannDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Claus BelkaDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.
Chukwuka EzeDepartment of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Farkhad.Manapov@med.uni-muenchen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 10% of small-cell lung cancer (SCLC) patients have brain metastases (BM) at initial diagnosis; more than 50% will develop BM within 2 years. BM are detected in up to 80% of all patients at autopsy. After primary treatment, prophylactic cranial irradiation (PCI) has been established as standard of care in SCLC patients responding to initial therapy. Based on level I evidence, PCI significantly decreases the risk of intracranial relapse and shows a modest survival benefit after 3 years. However, the role of PCI in defined patient subgroups such as resected SCLC, elderly and extensive stage patients with access to magnetic resonance imaging surveillance and stereotactic radiotherapy is yet to be fully clarified. Furthermore, strategies to effective prevention of neurocognitive decline after PCI remain unclear. All these factors significantly impact treatment decision making and should be evaluated in prospective settings. New concepts such as hippocampal avoidance and drug neuroprotection prevent chronic neurocognitive effects reducing treatment-related side effects of PCI. The aim of this review is to present a summary and update of the latest evidence for patient selection, efficacy and outcome of PCI.

Indexed as

neurocognitionpatient selectionPCIsmall-cell lung cancertreatment

Identifiers

PMID30323698
PMCPMC6181088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.